Press release Biocartis Group NV: Biocartis Announces Restart of its High-Throughput Cartridge Manufacturing Line
23 September 2021 - 7:00AM
Press release Biocartis Group NV: Biocartis Announces Restart of
its High-Throughput Cartridge Manufacturing Line
PRESS RELEASE: 23 September 2021, 07:00 CEST
Biocartis Announces Restart of its
High-Throughput Cartridge Manufacturing Line
Mechelen,
Belgium, 23 September
2021 – Biocartis Group NV (the ‘Company’ or
‘Biocartis’), an innovative molecular diagnostics company (Euronext
Brussels: BCART), today announces the restart of its
high-throughput ‘ML2’ cartridge manufacturing line.
Following a fire that broke out at one of the
Company’s warehouse facilities in Mechelen (Belgium) during the
night of 30 July 2021, production at the ML2 line was temporarily
suspended due to the need for structural repairs to the building
and select supporting systems. Those repairs, as well as several
subsequent control and quality related procedures, were completed
earlier this week. This led to the successful restart of the ML2
line in the night of 21 September 2021.
Herman Verrelst, Chief Executive Officer
of Biocartis, reacted: “I am very pleased to announce that
as from today, commercial cartridge production on the ML2 line has
resumed. Our teams have worked tremendously hard to get the ML2
line up and running again after the fire incident. We can be proud
of this accomplishment which shows the strength and resilience of
our teams.”
Earlier this month, on 2 September 2021 at the
announcement of its H1 2021 results, Biocartis had confirmed its
40% cartridge volume growth target for 2021, however subject to the
restart of the ML2 line and to the timely availability of reagent
raw materials for Idylla™ cartridges in sufficient quantities. With
the ML2 line now restarted, the Company is continuing efforts to
secure the supply of certain assay-specific reagents, to be able to
utilize the full capacity of the ML2 line and to minimize potential
temporary unavailability of certain Idylla™ products.
--- END ---
More information:
Renate DegraveHead of Corporate Communications & Investor
Relations
Biocartise-mail rdegrave@biocartis.com
tel
+32 15 631 729
mobile +32 471 53
60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer, as well as for
SARS-CoV-2/flu/RSV and sepsis. More
information: www.biocartis.com. Follow us on Twitter:
@Biocartis_. Biocartis and Idylla™ are registered trademarks in
Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Apr 2023 bis Apr 2024